Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Andrea Barp, Francesca Gerardi, Andrea Lizio, Valeria Ada Sansone & Christian Lunetta. (2020) Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials. Expert Opinion on Emerging Drugs 25:2, pages 145-164.
Read now
Read now
Arens Taga & Nicholas J. Maragakis. (2018) Current and emerging ALS biomarkers: utility and potential in clinical trials. Expert Review of Neurotherapeutics 18:11, pages 871-886.
Read now
Read now
Ana Martinez, Maria del Valle Palomo Ruiz, Daniel I. Perez & Carmen Gil. (2017) Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs 26:4, pages 403-414.
Read now
Read now
Svitlana Garbuzova-Davis, Avery Thomson, Crupa Kurien, R. Douglas Shytle & Paul R. Sanberg. (2016) Potential new complication in drug therapy development for amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 16:12, pages 1397-1405.
Read now
Read now
H Blasco, F Patin, CR Andres, P Corcia & PH Gordon. (2016) Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opinion on Pharmacotherapy 17:12, pages 1669-1682.
Read now
Read now
H. Blasco, P. Vourc’h, P. F. Pradat, P. H. Gordon, C. R. Andres & P. Corcia. (2016) Further development of biomarkers in amyotrophic lateral sclerosis. Expert Review of Molecular Diagnostics 16:8, pages 853-868.
Read now
Read now
Ali Aamer Habib & Hiroshi Mitsumoto. (2011) Emerging drugs for amyotrophic lateral sclerosis. Expert Opinion on Emerging Drugs 16:3, pages 537-558.
Read now
Read now
Articles from other publishers (18)
Charis Wong, Jenna M Gregory, Jing Liao, Kieren Egan, Hanna M Vesterinen, Aimal Ahmad Khan, Maarij Anwar, Caitlin Beagan, Fraser S Brown, John Cafferkey, Alessandra Cardinali, Jane Yi Chiam, Claire Chiang, Victoria Collins, Joyce Dormido, Elizabeth Elliott, Peter Foley, Yu Cheng Foo, Lily Fulton-Humble, Angus B Gane, Stella A Glasmacher, Áine Heffernan, Kiran Jayaprakash, Nimesh Jayasuriya, Amina Kaddouri, Jamie Kiernan, Gavin Langlands, D Leighton, Jiaming Liu, James Lyon, Arpan R Mehta, Alyssa Meng, Vivienne Nguyen, Na Hyun Park, Suzanne Quigley, Yousuf Rashid, Andrea Salzinger, Bethany Shiell, Ankur Singh, Tim Soane, Alexandra Thompson, Olaf Tomala, Fergal M Waldron, Bhuvaneish T Selvaraj, Jeremy Chataway, Robert Swingler, Peter Connick, Suvankar Pal, Siddharthan Chandran & Malcolm Macleod. (2023) Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus. BMJ Open 13:2, pages e064169.
Crossref
Crossref
JingSi Jiang, Yan Wang & Min Deng. (2022) New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Frontiers in Pharmacology 13.
Crossref
Crossref
Charis Wong, Rachel S Dakin, Jill Williamson, Judith Newton, Michelle Steven, Shuna Colville, Maria Stavrou, Jenna M Gregory, Elizabeth Elliott, Arpan R Mehta, Jeremy Chataway, Robert J Swingler, Richard Anthony Parker, Christopher J Weir, Nigel Stallard, Mahesh K B Parmar, Malcolm R Macleod, Suvankar Pal & Siddharthan Chandran. (2022) Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open 12:7, pages e064173.
Crossref
Crossref
Marie Dreger, Robert Steinbach, Markus Otto, Martin R Turner & Julian Grosskreutz. (2022) Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 93:4, pages 422-435.
Crossref
Crossref
A. Diana & P. Bongioanni. 2022. Glutamate and Neuropsychiatric Disorders. Glutamate and Neuropsychiatric Disorders
359
380
.
Michail S. Kukharsky, Veronika I. Skvortsova, Sergey O. Bachurin & Vladimir L. Buchman. (2020) In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches. Medicinal Research Reviews 41:5, pages 2804-2822.
Crossref
Crossref
Matthew C. Kiernan, Steve Vucic, Kevin Talbot, Christopher J. McDermott, Orla Hardiman, Jeremy M. Shefner, Ammar Al-Chalabi, William Huynh, Merit Cudkowicz, Paul Talman, Leonard H. Van den Berg, Thanuja Dharmadasa, Paul Wicks, Claire Reilly & Martin R. Turner. (2020) Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology 17:2, pages 104-118.
Crossref
Crossref
Débora Lanznaster, Rudolf C. Hergesheimer, Salah Eddine Bakkouche, Stephane Beltran, Patrick Vourc’h, Christian R. Andres, Diane Dufour-Rainfray, Philippe Corcia & Hélène Blasco. (2020) Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 21:8, pages 2911.
Crossref
Crossref
Rangariroyashe Hannah Chipika, Eoin Finegan, Stacey Li Hi Shing, Orla Hardiman & Peter Bede. (2019) Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS. Frontiers in Neurology 10.
Crossref
Crossref
Loqman A. Mohamed, Shashirekha Markandaiah, Silvia Bonanno, Piera Pasinelli & Davide Trotti. (2017) Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. The AAPS Journal 19:6, pages 1600-1614.
Crossref
Crossref
Lucas T. Vu & Robert Bowser. (2016) Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics 14:1, pages 119-134.
Crossref
Crossref
Michael Benatar, Kevin Boylan, Andreas Jeromin, Seward B. Rutkove, James Berry, Nazem Atassi & Lucie Bruijn. (2016) ALS biomarkers for therapy development: State of the field and future directions. Muscle & Nerve 53:2, pages 169-182.
Crossref
Crossref
Nadine Bakkar, Ashley Boehringer & Robert Bowser. (2015) Use of biomarkers in ALS drug development and clinical trials. Brain Research 1607, pages 94-107.
Crossref
Crossref
Brian A. Wall, Janet Wangari-Talbot, Seung S. Shin, Devora Schiff, Jairo Sierra, Lumeng J. Yu, Atif Khan, Bruce Haffty, James S. Goydos & Suzie Chen. (2014) Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell & Melanoma Research 27:2, pages 263-274.
Crossref
Crossref
Alida Spalloni, Michele Nutini & Patrizia Longone. (2013) Role of the N-methyl-d-aspartate receptors complex in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1832:2, pages 312-322.
Crossref
Crossref
Matthew Gladman, Merit Cudkowicz & Lorne Zinman. (2012) Enhancing clinical trials in neurodegenerative disorders. Current Opinion in Neurology 25:6, pages 735-742.
Crossref
Crossref
Todd D. Levine, Robert Bowser, Nicole C. Hank, Stephen Gately, Dietrich Stephan, David S. Saperstein & Kendall Van Keuren-Jensen. (2012) A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression. Neurology Research International 2012, pages 1-6.
Crossref
Crossref
Paul H. Gordon & Vincent Meininger. (2011) How can we improve clinical trials in amyotrophic lateral sclerosis?. Nature Reviews Neurology 7:11, pages 650-654.
Crossref
Crossref